Signal Transduction Pathway Mutations in Gastrointestinal (Gi) Cancers: A Systematic Review and Meta-Analysis Publisher Pubmed



Tabibzadeh A¹ ; Tameshkel FS^{2, 3} ; Moradi Y⁴ ; Soltani S⁵ ; Moradilakeh M^{3, 6} ; Ashrafi GH⁷ ; Motamed N⁸ ; Zamani F³ ; Motevalian SA⁹ ; Panahi M³ ; Esghaei M¹ ; Ajdarkosh H³ ; Mousavijarrahi A¹⁰ ; Niya MHK³ Show Affiliations
Source: Scientific Reports Published:2020

Abstract

The present study was conducted to evaluate the prevalence of the signaling pathways mutation rate in the Gastrointestinal (GI) tract cancers in a systematic review and meta-analysis study. The study was performed based on the PRISMA criteria. Random models by confidence interval (CI: 95%) were used to calculate the pooled estimate of prevalence via Metaprop command. The pooled prevalence indices of signal transduction pathway mutations in gastric cancer, liver cancer, colorectal cancer, and pancreatic cancer were 5% (95% CI: 3–8%), 12% (95% CI: 8–18%), 17% (95% CI: 14–20%), and 20% (95% CI: 5–41%), respectively. Also, the mutation rates for Wnt pathway and MAPK pathway were calculated to be 23% (95% CI, 14–33%) and 20% (95% CI, 17–24%), respectively. Moreover, the most popular genes were APC (in Wnt pathway), KRAS (in MAPK pathway) and PIK3CA (in PI3K pathway) in the colorectal cancer, pancreatic cancer, and gastric cancer while they were beta-catenin and CTNNB1 in liver cancer. The most altered pathway was Wnt pathway followed by the MAPK pathway. In addition, pancreatic cancer was found to be higher under the pressure of mutation compared with others based on pooled prevalence analysis. Finally, APC mutations in colorectal cancer, KRAS in gastric cancer, and pancreatic cancer were mostly associated gene alterations. © 2020, The Author(s).